MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
ALNA - Allena Pharmaceuticals Inc
$1.74
0.06(3.57%)9:00:00 PM 3/1/2021
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Newton, Massachusetts.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
Stock Statistics
MarketCap66.4M
PE Ratio
PEG Ratio
P/B3.5
P/S (ttm)
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %2%
Held by Institutions %42%
1 Day Vol Adjusted Return0.7
1 Month Vol Adjusted Return0.1
3 Month Vol Adjusted Return4.3
6 Month Vol Adjusted Return3.4
20 Days SMA Price ZScore-1.0
50 Days SMA Price ZScore0.3
12 -26 Days PPO0.6
1 Month Average Short Volume Ratio38.8
1 Day Volume Change ZScore-1.9
1 Month Daily Vol5.4
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    02/24/2021ALNA
    Allena Pharmaceuticals to Present at Upcoming Investor Conferences in March

    NEWTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in March: Cowen’s 41st Annual Health Care Conference Louis Brenner, M.D., Allena’s President and Chief Executive Offi...

    02/5/2021ALNA
    Are Institutions Heavily Invested In Allena Pharmaceuticals, Inc.'s (NASDAQ:ALNA) Shares?

    A look at the shareholders of Allena Pharmaceuticals, Inc. ( NASDAQ:ALNA ) can tell us which group is most powerful...

    02/2/2021ALNA
    Allena Pharmaceuticals Appoints Richard D. Katz, M.D. as Chief Financial Officer

    -- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) --NEWTON, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Richard D. Katz, M.D., as Chief Financial Officer (CFO), effective immediately. Dr. Katz succeeds Edward W...

    01/12/2021ALNA
    Allena Pharmaceuticals, Inc. (ALNA) Moves to Buy: Rationale Behind the Upgrade

    Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

    01/12/2021ALNA
    Has Allena Pharmaceuticals (ALNA) Outpaced Other Medical Stocks This Year?

    Is (ALNA) Outperforming Other Medical Stocks This Year?

    01/4/2021ALNA
    Allena Pharmaceuticals to Present at Upcoming Investor Conferences in January

    NEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in January: H.C. Wainwright Bioconnect 2021 Conference * Louis Brenner, M.D., Allena’s President and Chief Executi...

    12/2/2020ALNA
    Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million

    NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 10,400,000 shares of common stock of the ...

    12/1/2020ALNA
    Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering

    NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,000,000 shares of common stock ...